California Water Service Group Reschedules First Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
California Water Service Group Reschedules First Quarter 2013 Earnings Results Announcement and Teleconference

SAN JOSE, CA--(Marketwired - Apr 11, 2013) - California Water Service Group ( NYSE : CWT ) announced today that its first quarter earnings results will be released after market-close on Wednesday, May 1, 2013, and its teleconference will be held at 11:00 a.m. ET on Thursday, May 2, 2013.

In a press release dated April 8, 2013, the company initially announced that its first quarter earnings results would be released on April 24, 2013, and its teleconference would be held on April 25, 2013. The later date announced today is consistent with the date the company has released its earnings in prior years.

All stockholders and interested investors are invited to listen to the teleconference. The conference call may be accessed by dialing 1-888-438-5491 or 1-719-325-2361 and keying in ID# 3539432. A replay of the call will be available from 2:00 p.m. ET on Thursday, May 2, 2013, through June 30, 2013, at 1-888-203-1112 or 1-719-457-0820, ID# 3539432. The call will be hosted by President and Chief Operating Officer Martin A. Kropelnicki and Vice President and Chief Financial Officer Thomas F. Smegal. It will also be webcast under the investor relations tab at www.calwatergroup.com .

California Water Service Group is the parent company of California Water Service Company, Washington Water Service Company, New Mexico Water Service Company, Hawaii Water Service Company, Inc., CWS Utility Services, and HWS Utility Services. Together these companies provide regulated and non-regulated water service to nearly 2 million people in California, Washington, New Mexico, and Hawaii. California Water Service Group's common stock trades on the New York Stock Exchange under the symbol "CWT." Additional information is available on our web site at www.calwatergroup.com .

Some of the information included in this press release contains forward-looking statements, such as statements related to the offering and the issuance and sale of common stock (including the expected timing of closing of the offering), and the availability of a final prospectus supplement, which are made pursuant to the safe-harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Because these forward-looking statements involve numerous risks and uncertainties, there are important factors that could cause our actual results to differ materially from those in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future events. The events or circumstances reflected in the forward-looking statements might not occur. You can identify forward-looking statements by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," " forecasting," "pro forma," "estimates" or "anticipates" or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indicators of whether, or the time at which, such performance or results will be achieved. There is no assurance that the events or circumstances reflected in forward-looking statements will occur or be achieved. Forward-looking statements are necessarily dependent on assumptions, data or methods that may be incorrect or imprecise and we may not be able to realize them. We caution you not to place undue reliance on forward-looking statements, which reflect our analysis only and speak as of the date of this press release or as of the dates indicated in the statements. All of our forward-looking statements are qualified in their entirety by this statement. We assume no obligation to update or supplement forward-looking statements. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements contained in this press release: any material adverse change in the financial or securities markets within or outside the United States or in political, financial or economic conditions within or outside the United States or any material outbreak or material escalation of hostilities within or outside the United States or declaration by the United States of a national emergency or war or other material calamity or crisis within or outside the United States, including, without limitation, an act of terrorism, any suspension or limitation of trading in securities generally or in any of the securities of Cal Water by the SEC, by any exchange that lists such securities or in any over-the-counter market, any declaration by any governmental authority of a general banking moratorium, any financial market fluctuations, actual or perceived changes in general economic conditions, global trade or in the real estate sector, inflation risks, an actual or perceived downturn in the U.S., California or global economy, and certain other matters discussed under the heading "Risk Factors" and elsewhere in our annual report on Form 10-K for the year ended December 31, 2012.

1720 North First Street San Jose, CA 95112-4598

Contact: Tom Smegal (408) 367-8200 (analysts) Shannon Dean (310) 257-1435 (media)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading